Tango Therapeutics

Company snapshot

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 9 US patent(s) indexed to this assignee profile.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Tango Therapeutics. Not investment advice.

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 32.4

• Peer + 0 momentum

  Oncolytics Biotech

  TA overlap score 24.6

• Peer + 0 momentum

  Compass Therapeutics

  TA overlap score 23

• Peer + 0 momentum

  Sichuan Baili Pharmaceutical

  TA overlap score 20.8

Recent activity

Latest pipeline, patent, and corporate events for Tango Therapeutics.

1. Jun 8, 2026 Clinical update

   TNG908-C101 — Phase 2

2. May 23, 2026 Clinical update

   S095035 — Phase 2

3. May 23, 2026 Clinical update

   TNG260 — Phase 2

4. May 23, 2026 Clinical update

   TNG348 — Phase 2

5. May 23, 2026 Clinical update

   TNG456 — Phase 2

View all clinical trial activity →

• What is Tango Therapeutics?

  Tango Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker TNGX. Primary therapeutic focus areas include Non Small Cell Lung Cancer, Locally Advanced Solid Tumor, MTAP-deleted Solid Tumors, Breast Cancer. NovaPharmaNews links 7 clinic

• Is Tango Therapeutics publicly traded?

  Yes. Tango Therapeutics is listed with ticker TNGX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Tango Therapeutics develop or market?

  We link 2 drug profile(s) where Tango Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/tango-therapeutics#company-drugs.

• What are the latest developments for Tango Therapeutics?

  In the last 12 months our linked public records show 7 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Tango Therapeutics focus on?

  Tango Therapeutics focuses on Non Small Cell Lung Cancer, Locally Advanced Solid Tumor, MTAP-deleted Solid Tumors based on our analysis of their pipeline programs and drug development activities.